Induced pluripotent stem cell (iPSCs) and their application in immunotherapy

Cellular and Molecular Immunology

Volumn 11, Issue 1, 2014, Pages 17-24

  Jiang, Zhengping ^a   Han, Yanmei ^a   Cao, Xuetao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Differentiation; Hematopoietic cell; Immunogenicity; Immunotherapy; Induced pluripotent stem cells

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; CELL DIFFERENTIATION; CLINICAL MEDICINE; CYTOKINE PRODUCTION; HEMATOPOIETIC STEM CELL; HISTOCOMPATIBILITY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NONHUMAN; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; REVIEW; SICKLE CELL ANEMIA;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; HUMANS; IMMUNOTHERAPY; INDUCED PLURIPOTENT STEM CELLS;

EID: 84891783949     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2013.62     Document Type: Review

References (62)

1. Odorico JS, Kaufman DS, Thomson JA. Multilineage differentiation from human embryonic stem cell lines. Stem Cells 2001; 19: 193-204.
2. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981; 292: 154-156.
3. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
4. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920.
5. Stadtfeld M, Nagaya M, Utikal J, Weir G, Hochedlinger K. Induced pluripotent stem cells generated without viral integration. Science 2008; 322: 945-949.
6. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008; 322: 949-953.
7. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009; 324: 797-801.
8. Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009; 4: 381-384.
9. Cho HJ, Lee CS, Kwon YW, Paek JS, Lee SH, Hur J et al. Induction of pluripotent stem cells from adult somatic cells by protein-based reprogramming without genetic manipulation. Blood 2010; 116: 386-395.
10. Hou P, Li Y, Zhang X, Liu C, Guan J, Li H et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 2013; 341: 651-654.
11. Rais Y, Zviran A, Geula S, Gafni O, Chomsky E, Viukov S et al. Deterministic direct reprogramming of somatic cells to pluripotency. Nature 2013; 502: 65-70.
12. Abad M, Mosteiro L, Pantoja C, Canamero M, Rayon T, Ors I et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature 2013; 502: 340-345.
13. Chang KH, Nelson AM, Cao H, Wang L, Nakamoto B, Ware CB et al. Definitive-like erythroid cells derived from human embryonic stem cells coexpress high levels of embryonic and fetal globins with little or no adult globin. Blood 2006; 108: 1515-1523.
14. Olivier EN, Qiu C, Velho M, Hirsch RE, Bouhassira EE. Large-scale production of embryonic red blood cells from human embryonic stem cells. Exp Hematol 2006; 34: 1635-1642.
15. Lu SJ, Feng Q, Park JS, Vida L, Lee BS, Strausbauch M et al. Biologic properties and enucleation of red blood cells from human embryonic stem cells. Blood 2008; 112: 4475-4484.
16. Ma F, Ebihara Y, Umeda K, Sakai H, Hanada S, Zhang H et al. Generation of functional erythrocytes from human embryonic stem cell-derived definitive hematopoiesis. Proc Natl Acad Sci USA 2008; 105: 13087-13092.
17. Karlsson KR, Cowley S, Martinez FO, Shaw M, Minger SL, James W. Homogeneous monocytes and macrophages from human embryonic stem cells following coculture-free differentiation in M-CSF and IL-3. Exp Hematol 2008; 36: 1167-1175.
18. Zhan X, Dravid G, Ye Z, Hammond H, Shamblott M, Gearhart J et al. Functional antigen-presenting leucocytes derived from human embryonic stem cells in vitro. Lancet 2004; 364: 163-171.
19. Takayama N, Nishikii H, Usui J, Tsukui H, Sawaguchi A, Hiroyama T et al. Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. Blood 2008; 111: 5298-5306.
20. Woll PS, Grzywacz B, Tian X, Marcus RK, Knorr DA, Verneris MR et al. Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood 2009; 113: 6094-6101.
21. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008; 451: 141-146.
22. Ye Z, Zhan H, Mali P, Dowey S, Williams DM, Jang YY et al. Humaninduced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 2009; 114: 5473-5480.
23. Grigoriadis AE, Kennedy M, Bozec A, Brunton F, Stenbeck G, Park IH et al. Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. Blood 2010; 115: 2769-2776.
24. Choi KD, Yu J, Smuga-Otto K, Salvagiotto G, Rehrauer W, Vodyanik M et al. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells 2009; 27: 559-567.
25. + progenitors. J Clin Invest 2009; 119: 2818-2829.
26. Lapillonne H, Kobari L, Mazurier C, Tropel P, Giarratana MC, Zanella-Cleon I et al. Red blood cells generation from human induced pluripotent stem cells: perspectives for transfusion medicine. Haematologica 2010; 95: 1651-1659.
27. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007; 318: 1920-1923.
28. Raya A, Rodriguez-Piza I, Guenechea G, Vassena R, Navarro S, Barrero MJ et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009; 460: 53-59.
29. Lei F, Haque R, Weiler L, Vrana KE, Song J. T lineage differentiation from induced pluripotent stem cells. Cell Immunol 2009; 260: 1-5.
30. Schmitt TM, de Pooter RF, Gronski MA, Cho SK, Ohashi PS, Zuniga-Pflucker JC. Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat Immunol 2004; 5: 410-417.
31. La Motte-Mohs RN, Herer E, Zuniga-Pflucker JC. Induction of T-cell development from human cord blood hematopoietic stem cells by Delta-like 1 in vitro. Blood 2005; 105: 1431-1439.
32. Ye Z, Cheng L. Potential of human induced pluripotent stem cells derived from blood and other postnatal cell types. Regen Med 2010; 5: 521-530.
33. Polo JM, Liu S, Figueroa ME, Kulalert W, Eminli S, Tan KY et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 2010; 28: 848-855.
34. Taniguchi M, Harada M, Kojo S, Nakayama T, Wakao H. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 2003; 21: 483-513.
35. + natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol Rev 2007; 220: 183-198.
36. Watarai H, Fujii S, Yamada D, Rybouchkin A, Sakata S, Nagata Y et al. Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cells. J Clin Invest 2010; 120: 2610-2618.
37. Senju S, Haruta M, Matsunaga Y, Fukushima S, Ikeda T, Takahashi K et al. Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells. Stem Cells 2009; 27: 1021-1031.
38. Ales NC, Katial RK. Vaccines against biologic agents: uses and developments. Respir Care Clin N Am 2004; 10: 123-146.
39. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
40. Li J, Gao GD, Yuan TF. Cell based vaccination using transplantation of iPSC-derived memory B cells. Vaccine 2009; 27: 5728-5729.
41. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011; 474: 212-215.
42. Guha P, Morgan JW, Mostoslavsky G, Rodrigues NP, Boyd AS. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 2013; 12: 407-412.
43. Araki R, Uda M, Hoki Y, Sunayama M, Nakamura M, Ando S et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2013; 494: 100-104.
44. Chen HF, Yu CY, Chen MJ, Chou SH, Chiang MS, Chou WH et al. Characteristic expression of major histocompatibility complex and immune privilege genes in human pluripotent stem cells and the derivatives. Cell Transplant 2013; in press.
45. Kulkeaw K, Horio Y, Mizuochi C, Ogawa M, Sugiyama D. Variation in hematopoietic potential of induced pluripotent stem cell lines. Stem Cell Rev 2010; 6: 381-389.
46. Taylor CJ, Peacock S, Chaudhry AN, Bradley JA, Bolton EM. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell 2012; 11: 147-152.
47. Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S et al. A more efficient method to generate integration-free human iPS cells. Nat Methods 2011; 8: 409-412.
48. Okita K, Nagata N, Yamanaka S. Immunogenicity of induced pluripotent stem cells. Circ Res 2011; 109: 720-721.
49. Kaneko S, Yamanaka S. To be immunogenic, or not to be: that's the iPSC question. Cell Stem Cell 2013; 12: 385-386.
50. Taylor CJ, Bolton EM, Pocock S, Sharples LD, Pedersen RA, Bradley JA. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet 2005; 366: 2019-2025.
51. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A et al. Disease-specific induced pluripotent stem cells. Cell 2008; 134: 877-886.
52. Ghosh Z, Wilson KD, Wu Y, Hu S, Quertermous T, Wu JC. Persistent donor cell gene expression among human induced pluripotent stem cells contributes to differences with human embryonic stem cells. PLoS ONE 2010; 5: e8975.
53. Li JY, Christophersen NS, Hall V, Soulet D, Brundin P. Critical issues of clinical human embryonic stem cell therapy for brain repair. Trends Neurosci 2008; 31: 146-153.
54. Graf T, Stadtfeld M. Heterogeneity of embryonic and adult stem cells. Cell Stem Cell 2008; 3: 480-483.
55. Huang S. Reprogramming cell fates: reconciling rarity with robustness. Bioessays 2009; 31: 546-560.
56. Gutierrez-Aranda I, Ramos-Mejia V, Bueno C, Munoz-Lopez M, Real PJ, Macia A et al. Human induced pluripotent stem cells develop teratoma more efficiently and faster than human embryonic stem cells regardless the site of injection. Stem Cells 2010; 28: 1568-1570.
57. Saric T, Frenzel LP, Hescheler J. Immunological barriers to embryonic stem cell-derived therapies. Cells Tissues Organs 2008; 188: 78-90.
58. Dressel R, Nolte J, Elsner L, Novota P, Guan K, Streckfuss-Bomeke K et al. Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells. FASEB J 2010; 24: 2164-2177.
59. Kuroda Y, Kitada M, Wakao S, Nishikawa K, Tanimura Y, Makinoshima H et al. Unique multipotent cells in adult human mesenchymal cell populations. Proc Natl Acad Sci USA 2010; 107: 8639-8643.
60. Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Sudhof TC, Wernig M. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 2010; 463: 1035-1041.
61. Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 2008; 455: 627-632.
62. Tang H, Guo Z, Zhang M, Wang J, Chen G, Cao X. Endothelial stroma programs hematopoietic stem cells to differentiate into regulatory dendritic cells through IL-10. Blood 2006; 108: 1189-1197.